IQOS uptake and history of tobacco product use: findings from cross-sectional surveys in Japan, Italy, and Germany Presentations presentations Long-Term Assessmentlongtermassessment Sep 24, 2020 20200924 /content/dam/pmiscience/default-fallback-thumbnails/publication/pmi-science-laboratory-work-default-thumbnail.png
      Presentations

      IQOS uptake and history of tobacco product use: findings from cross-sectional surveys in Japan, Italy, and Germany

      Roulet, S.

      Conference date
      Sep 24, 2020
      Conference name
      3rd Scientific Summit on Tobacco Harm Reduction: Novel producs, Research & Policy
      Topic
      Summary

      Our scientists presented at the 3rd Scientific Summit on Tobacco Harm Reduction: Novel products, Research & Policy on September 24, 2020 by pre-recording themselves presenting their posters. In this video, Roulet focuses on the IQOS uptake and history of tobacco product use with findings from cross-sectional surveys in Japan, Italy, and Germany.

      Related Publications

      Ischemic Heart Disease and Chronic Obstructive Pulmonary Disease Hospitalizations in Japan Before and After the Introduction of a Heated Tobacco Product

      Long-Term Assessment

      Post-market evidence on alternative nicotine-containing products

      Long-Term Assessment

      IQOS uptake and history of tobacco product use: findings from cross-sectional surveys in Japan, Italy, and Germany

      Long-Term Assessment

      A proposed approach for evaluating harm reduction in adult smokers after switching from cigarettes to tobacco heating system (THS): biomarkers of potential harm

      Long-Term Assessment

      Influence of the Introduction of Heated Tobacco Products on IHD and COPD Hospitalizations in Japan using Real-World Data

      Long-Term Assessment

      IQOS Use Prevalence and History of Tobacco Product Use: Findings from Surveys in Japan, Italy, and Germany

      Long-Term Assessment

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts to develop and assess products that have the potential to reduce individual risk and population harm associated with tobacco use. This site is for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not for advertising or marketing. It is not intended for use by consumers.

      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. Our RRPs are smoke-free products that produce an aerosol that contains far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.